Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study

Prajs, Iwona; Kuliczkowski, Kazimierz

doi:10.17219/acem/68578

Cited by 4 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies investigated relationship between MPV, JAK2 mutational status and history of thrombosis with inconsistent findings among studies. Only one work reported statistically significant result for MPV and history of thrombosis in ET [29]. Similarly, higher MPV was associated with JAK2 mutation in two studies [31,32], whereas result did not reach statistical significance or was not tested in other.…”

Section: Discussionmentioning

confidence: 95%

“…We identified six previous studies [21,22,[29][30][31][32] assessing role of MPV in Ph-MPN patients (PMF patients comprised a minority of analyzed populations in two works [21,22] and were not included in other studies). These studies investigated relationship between MPV, JAK2 mutational status and history of thrombosis with inconsistent findings among studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis

et al. 2017

View full text Add to dashboard Cite

Neoplastic megakaryopoiesis is a dominant feature of Philadelphia-chromosome-negative myeloproliferative neoplasms (Ph- MPNs), and elevated mean-platelet-volume (MPV) is a common finding in these diseases. The clinical and prognostic significances of MPV in patients with primary (PMF) and secondary myelofibrosis (SMF) have not been reported. We retrospectively analyzed 87 patients with myelofibrosis (66 with PMF, 21 with SMF) treated at our institution. MPV was recorded in addition to other hematological and clinical parameters. MPV was elevated in both PMF and SMF patients in comparison to controls, whereas there was no statistically significant difference between PMF and SMF. Elevated MPV was associated with lower platelets (P = 0.016), higher white blood cells (P = 0.015), higher percentage of circulatory blasts (P = 0.009), higher lactate dehydrogenase (P = 0.011), larger spleen size (P = 0.014) and higher Dynamic International Prognostic score category (P = 0.027), while there was no statistically significant association with driver mutations or degree of bone marrow fibrosis. Higher MPV was univariately associated with inferior overall survival in the whole cohort (HR = 3.82, P = 0.006), PMF (HR = 4.35, P = 0.007) and SMF patients (HR = 7.22, P = 0.034). These associations remained significant in multivariate analyses adjusted for DIPSS. Higher MPV is associated with more aggressive disease features and exhibits powerful independent prognostic properties in both PMF and SMF settings.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…18 In addition to the above mentioned thrombotic risk factors, there are additional factors that contribute to the increased risk of thrombosis: leukocytosis and leuko-trombocyte aggregates, P selectin expression and granulocyte tissue factor, increase mean platelet volume. 19,20 In the evaluation of the important thrombotic risk to be assessed, there are also the presence of thrombophilia, the qualitative changes in platelets and the degree of expression of the platelet derived micro particles. Non-cirrhotic, non-malignant portal vein thrombosis, not associated with acute abdominal inflammation or abdominal surgery, is often due to thrombophilia.…”

Section: Factorsmentioning

confidence: 99%

“…However, not all studies have shown the importance of the presence of these mutations in increasing the risk of thrombophilia. 20 It seems to be important only the association of the presence of Factor V Leiden that increases the risk of thrombotic complications. 24 Platelet has a very important role in the occurrence of thrombotic complications.…”

Section: Factorsmentioning

confidence: 99%

Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm

Popov¹,

Andreescu²,

Vlădăreanu³

et al. 2018

HTIJ

View full text Add to dashboard Cite

“…ET is associated with an increased risk of thrombosis and/or haemorrhage, as well as progression to myelofibrosis (Passamonti et al , ; Barbui, ). The most important risk factors include previous thromboembolic events, age >60 years, and JAK2 V617F mutation (Barbui et al , ; Prajs & Kuliczkowski, ). Cytoreductive therapy is recommended for these patients (Barbui et al , ).…”

mentioning

confidence: 99%

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial

et al. 2019

View full text Add to dashboard Cite

Summary Anagrelide is an established treatment option for essential thrombocythaemia ( ET ). A prolonged release formulation was developed with the aim of reducing dosing frequency and improving tolerability, without diminishing efficacy. This multicentre, randomized, double blind, active‐controlled, non‐inferiority trial investigated the efficacy, safety and tolerability of anagrelide prolonged release (A‐ PR ) over a reference product in high‐risk ET patients, either anagrelide‐naïve or ‐experienced. In a 6 to 12‐week titration period the individual dose for the consecutive 4‐week maintenance period was identified. The primary endpoint was the mean platelet count during the maintenance period (3 consecutive measurements, day 0, 14, 28). Of 112 included patients 106 were randomized. The mean screening platelet counts were 822 × 10 9 /l (95% confidence interval ( CI ) 707–936 × 10 9 /l) and 797 × 10 9 /l (95% CI 708–883 × 10 9 /l) for A‐ PR and the reference product, respectively. Both treatments effectively reduced platelet counts, to mean 281 × 10 9 /l for A‐ PR (95% CI 254–311) and 305 × 10 9 /l (95% CI 276–337) for the reference product ( P < 0·0001, for non‐inferiority). Safety and tolerability were comparable between both drugs. The novel prolonged‐release formulation was equally effective and well tolerated compared to the reference product. A‐ PR provides a more convenient dosing schedule and will offer an alternative to licensed immediate‐release anagrelide formulations.

show abstract

Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study

Abstract: Background. Thrombotembolic complications are the leading cause of mortality in essential thrombocythemia (ET), but the definition of thrombotic risk remains far from clear.

Cited by 4 publications

References 24 publications

Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis

Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis

Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial

Contact Info

Product

Resources

About